Russian biosimilar developer Biocad has announced that it will begin manufacturing its rituximab and bevacizumab biosimilars in Morocco. The 2 drugs, manufactured in partnership with Sothema Labs, will be sold in numerous markets in North Africa, including Morocco, Senegal, Gabon, and Cote d’Ivoire.
Russian biosimilar developer Biocad has announced that it will begin manufacturing its rituximab and bevacizumab biosimilars in Morocco. The 2 drugs, manufactured in partnership with Sothema Labs, will be sold in numerous markets in North Africa, including Morocco, Senegal, Gabon, and Cote d’Ivoire.
In a press release, Biocad indicated that its biosimilar products, priced at a 30% discount to their reference drugs, are expected to gain more than a 50% share of the market for these therapies. Biocad estimates that the North African market for anticancer monoclonal antibodies is worth $220 million in total.
“The efforts of our company combined with the eager enthusiasm of our Moroccan colleagues in transferring the production of biosimilars to North Africa has brought remarkable results,” said Dmitry Morozov, CEO of Biocad. “In the coming days, the drug products will go on sale. In my opinion, this is eloquent evidence that Russian companies can compete with leaders of the international market. Moreover, this is the first successful case of transferring technologies of the [monoclonal antibody] drug products manufacturing to North Africa amid the refusal of western companies to implement such projects.”
Biocad added that it has entered into an agreement to localize the manufacturing of finished dosage forms of its products in Algeria, though it did not release details of the Algerian partnership.
Biocad’s biosimilars have been making inroads into a number of global markets; in June, the company announced that it had obtained a marketing authorization for its rituximab product in Bolivia and Honduras, adding to its portfolio of markets that includes Kazakhstan, Vietnam, and Sri Lanka. The company has also sought a foothold in the European Union, and has invested heavily in projects in Finland’s Turku region as it seeks to develop its molecules for approval and commercialization in the European marketplace. The company plans to invest €25 million ($28 million) in Finland over the coming 7 years.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
Duke Publishes Recommendations for Developing CGT Biosimilars
October 9th 2024Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex biologics limit competition, requiring policies that support the development of biosimilars to enhance affordability and patient access.